Gene:
CDKN1B
cyclin-dependent kinase inhibitor 1B (p27, Kip1)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  KIP1; P27KIP1
PharmGKB Accession Id: PA105

Details

Cytogenetic Location: chr12 : p13.1 - p13.1
GP mRNA Boundary: chr12 : 12870302 - 12875305
GP Gene Boundary: chr12 : 12860302 - 12878305
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Celecoxib Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of celecoxib and candidate genes interacting with celecoxib and involved in the regulation of cell cycle, apoptosis and angiogenesis by celecoxib.

External Pathways

Links to non-PharmGKB pathways.

  1. cdk regulation of dna replication - (BioCarta via Pathway Interaction Database)
  2. cell cycle: g1/s check point - (BioCarta via Pathway Interaction Database)
  3. Class I PI3K signaling events mediated by Akt - (Pathway Interaction Database NCI-Nature Curated)
  4. ctcf: first multivalent nuclear factor - (BioCarta via Pathway Interaction Database)
  5. cyclins and cell cycle regulation - (BioCarta via Pathway Interaction Database)
  6. FOXA1 transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
  7. FoxO family signaling - (Pathway Interaction Database NCI-Nature Curated)
  8. influence of ras and rho proteins on g1 to s transition - (BioCarta via Pathway Interaction Database)
  9. Integrins in angiogenesis - (Pathway Interaction Database NCI-Nature Curated)
  10. pten dependent cell cycle arrest and apoptosis - (BioCarta via Pathway Interaction Database)
  11. regulation of p27 phosphorylation during cell cycle progression - (BioCarta via Pathway Interaction Database)
  12. Regulation of retinoblastoma protein - (Pathway Interaction Database NCI-Nature Curated)
  13. Regulation of Telomerase - (Pathway Interaction Database NCI-Nature Curated)
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
celecoxib
No related diseases are available

Publications related to CDKN1B: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. The pharmacogenomics journal. 2011. Gupta A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. The pharmacogenomics journal. 2010. Bonelli P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer research. 2010. Huang Xiaoping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Current cancer drug targets. 2009. Bedard Philippe L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008. Ben Sahra I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of molecular signaling. 2008. Zhuang Yongxian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science (New York, N.Y.). 2006. Yoon Andrew, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer research. 2004. Han Chang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003. Ross Mary E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Molecular cancer therapeutics. 2003. Fuino Lianne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Involvement of PKA and Sp1 in the induction of p27(Kip1) by tamoxifen. Biochemical pharmacology. 2003. Lee Te-Hsiu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World journal of gastroenterology : WJG. 2003. Wu Gao-Song, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. Journal of the American Society of Nephrology : JASN. 1999. Weiss R H, et al. PubMed

LinkOuts

Entrez Gene:
1027
OMIM:
600778
610755
UCSC Genome Browser:
NM_004064
RefSeq RNA:
NM_004064
RefSeq Protein:
NP_004055
RefSeq DNA:
AC_000055
AC_000144
NC_000012
NG_016341
NT_009714
NW_001838052
NW_925328
UniProtKB:
CDN1B_HUMAN (P46527)
Q6I9V6_HUMAN (Q6I9V6)
Ensembl:
ENSG00000111276
GenAtlas:
CDKN1B
GeneCard:
CDKN1B
MutDB:
CDKN1B
ALFRED:
LO176960D
HuGE:
CDKN1B
Comparative Toxicogenomics Database:
1027
ModBase:
P46527
HumanCyc Gene:
HS03396
HGNC:
1785

Common Searches